Khaled Benabed
YOU?
Author Swipe
View article: PB2086: SIMULTANEOUS DIAGNOSIS OF MULTIPLE MYELOMA AND MYELODYSPLASIA: CASE REPORT.
PB2086: SIMULTANEOUS DIAGNOSIS OF MULTIPLE MYELOMA AND MYELODYSPLASIA: CASE REPORT. Open
Topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research Background: We report here the case of an 82-year-old patient, Caucasian, with no notable history, presenting a long-standing thrombocytopenia (107 G/L…
View article: Simultaneous diagnosis of Multiple Myeloma and Myelodysplasia: A case report
Simultaneous diagnosis of Multiple Myeloma and Myelodysplasia: A case report Open
Multiple Myeloma (MM) and Myelodysplastic Syndrome (MDS) are two hematological malignancies with different clinico-biological features to their specific pathogenesis and evolution. The simultaneous occurrence of these two blood diseases wi…
View article: Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients
Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients Open
Hairy cell leukemia (cHCL) patients have, in most cases, a specific clinical and biological presentation with splenomegaly, anemia, leukopenia, neutropenia, monocytopenia and/or thrombocytopenia, identification of hairy cells that express …
View article: Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study
Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study Open
View article: ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies
ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies Open
In routine clinical practice in France, Zarzio is mostly used as primary prophylaxis for chemotherapy-induced neutropenia in patients with hematological malignancies. Patient-related risk factors appear to have more weight in clinicians' d…
View article: The prognostic value of hematogones in patients with acute myeloid leukemia
The prognostic value of hematogones in patients with acute myeloid leukemia Open
In acute myeloid leukemia (AML), new prognostic tools are needed to assess the risk of relapse. Hematogones (HGs) are normal B‐lymphocyte precursors that increase in hematological diseases and may influence remission duration in AML. HG de…